STAGEZERO LIFE SCIENC.
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more
Market Cap & Net Worth: STAGEZERO LIFE SCIENC. (61N1)
STAGEZERO LIFE SCIENC. (F:61N1) has a market capitalization of $2.22 Million (€2.16 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #34705 globally and #4021 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying STAGEZERO LIFE SCIENC.'s stock price €0.02 by its total outstanding shares 123553000 (123.55 Million).
STAGEZERO LIFE SCIENC. Market Cap History: 2016 to 2025
STAGEZERO LIFE SCIENC.'s market capitalization history from 2016 to 2025. Data shows change from $209.01 Million to $2.22 Million (-35.92% CAGR).
STAGEZERO LIFE SCIENC. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how STAGEZERO LIFE SCIENC.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 61N1 by Market Capitalization
Companies near STAGEZERO LIFE SCIENC. in the global market cap rankings as of March 18, 2026.
Key companies related to STAGEZERO LIFE SCIENC. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
STAGEZERO LIFE SCIENC. Historical Marketcap From 2016 to 2025
Between 2016 and today, STAGEZERO LIFE SCIENC.'s market cap moved from $209.01 Million to $ 2.22 Million, with a yearly change of -35.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €2.22 Million | 0.00% |
| 2024 | €2.22 Million | -16.67% |
| 2023 | €2.66 Million | -34.38% |
| 2022 | €4.06 Million | -81.07% |
| 2021 | €21.43 Million | -60.33% |
| 2020 | €54.03 Million | +104.81% |
| 2019 | €26.38 Million | -27.78% |
| 2018 | €36.53 Million | -64.00% |
| 2017 | €101.46 Million | -51.46% |
| 2016 | €209.01 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of STAGEZERO LIFE SCIENC. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.22 Million USD |
| MoneyControl | $2.22 Million USD |
| MarketWatch | $2.22 Million USD |
| marketcap.company | $2.22 Million USD |
| Reuters | $2.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.